Why Xylem (XYL) is on investors’ radar today
Xylem (XYL) has drawn fresh attention after recent trading left the stock with a return of about 10.6% over the past year, despite weaker performance in the past 3 months.
See our latest analysis for Xylem.
At a share price of $121.26, Xylem’s short term share price return has been weak, with a 30 day decline of 4.65% and a 90 day decline of 11.56%, even as the 1 year total shareholder return of 10.59% shows a more resilient longer term picture.
If this shift in momentum has you rethinking where growth might come from next, it could be worth scanning utilities and infrastructure peers in the 28 power grid technology and infrastructure stocks
So with Xylem trading around $121.26, showing solid 1-year returns and indications of an intrinsic discount, is the recent pullback providing a genuine entry point, or is the market already pricing in future growth?
Most Popular Narrative: 23.5% Undervalued
At a last close of $121.26 versus a narrative fair value of $158.41, the current price sits well below what this widely followed model suggests. This puts the focus squarely on how durable Xylem's growth and margin assumptions really are.
Successful post-acquisition integration of Evoqua and revenue synergies from services expansion are accelerating Xylem's shift toward more recurring, higher-margin aftermarket and services revenue streams, boosting earnings stability and long-term profitability.
Curious what kind of revenue mix, margin profile, and earnings path are baked into that fair value? The narrative leans heavily on recurring service income, disciplined integration, and a premium profit multiple that assumes those plans stay on track.
Result: Fair Value of $158.41 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a real risk that weaker orders in China and other developing markets, or delays in government funding cycles, could derail that upbeat narrative.
Find out about the key risks to this Xylem narrative.
Another Angle on Xylem’s Valuation
The SWS DCF model points to a fair value of $157.67 per share, with Xylem trading at $121.26. That gap suggests the price could be below what its forecast cash flows imply. However, how comfortable are you with the assumptions that sit inside that model?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
The mixed signals around Xylem’s recent share price and fair value estimates make it worth taking a closer look yourself and acting promptly. To see what optimism is already showing up in the data, review the 4 key rewards
Looking for more investment ideas?
If Xylem is on your screen already, do not stop there; widen your watchlist now so you are not relying on a single story for future returns.
- Scan for potential value opportunities by reviewing 63 high quality undervalued stocks, which combines strong fundamentals with prices that may not fully reflect their qualities.
- Prioritize resilience by checking out 67 resilient stocks with low risk scores, focusing on companies with characteristics that may support steadier performance across different market conditions.
- Spot potential future standouts by using screener containing 26 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com